Cellectis S.A. American Depositary Shares (CLLS) is a publicly traded Healthcare sector company. As of May 21, 2026, CLLS trades at $3.65 with a market cap of $387.35M and a P/E ratio of 0.00. CLLS moved +0.83% today. Year to date, CLLS is -19.38%; over the trailing twelve months it is +137.66%. Its 52-week range spans $1.10 to $5.48. Analyst consensus is buy with an average price target of $9.00. Rallies surfaces CLLS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Cellectis Posts $188 Million Cash, Cema-cel Delivers 58.3% MRD Negativity: Cellectis held $188 million in cash at March 31, 2026, funding operations into Q4 2027, and its ALPHA3 trial of cema-cel showed 58.3% MRD negativity versus 16.7% with no serious treatment-related events. Interim analysis of lasme-cel Phase 2 and full eti-cel Phase 1 data both arrive in Q4 2026.
| Metric | Value |
|---|---|
| Price | $3.65 |
| Market Cap | $387.35M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.48 |
| 52-Week Low | $1.10 |
| Volume | 11 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
1 analysts cover CLLS: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $9.00.